Neev Patel

Neev Patel

Auto-generated profile, based on publicly available information

Neev Patel

Stanford University, Department of Nephrology Palo Alto California USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 May 2022 in International Journal of Cardiology
Verified
Journal Article
Open access
PDF file
ZAZaki Al-Yafeai
Zaki Al-Yafeai
ACAlexander Carvajal-González
Alexander Carvajal-González
HAHamzah Abduljabar
Hamzah Abduljabar
MAMuhammed Arvas
Muhammed Arvas
SPShaan Patel
Shaan Patel
NPNeev Patel
Neev Patel
• Novel MS therapeutics have been recently approved by the FDA; however, the cardiovascular profile of these novel agents is poorly characterized. • CD20 and CD25 inhibitors are associated with a higher risk of AF, CAD and heart failure. • S1PR modulators are associated with significant bradycardia and AV block.

7 June 2020 in Cureus
Verified
Journal Article
Open access
PDF file
Rikinkumar S. PatelRikinkumar S. Patel
Rikinkumar S. Patel
NPNeev Patel
Neev Patel
MBMizba Baksh
Mizba Baksh
AZAnnam Zaidi
Annam Zaidi
JPJaiminkumar Patel
Jaiminkumar Patel
The ongoing pandemic of 2019 novel coronavirus (2019-nCoV), which originated from Wuhan, China, has led to 68,279 deaths due to 2019-nCoV pneumonia as of May 5, 2020. We conducted a systematic review and included 16 case reports to summarize the transmission and pathology of 2019-nCoV, and clinical presentation, laboratory and imaging findings, and treatment in 2019-nCoV pneumonia. The disease is mild in most people; in some, it may progress to severe pneumonia with acute respiratory distress syndrome (ARDS). Patients with mild illness usually recover at home, with supportive care and isolation in accordance with guidelines. Patients who have moderate to severe pneumonia are usually monitored in the hospital. Although there is no definitive treatment for 2019-nCoV pneumonia so far, some antiviral drugs have shown promising results. The use of lopinavir/ritonavir and remdesivir was associated with significant clinical improvement in severe pneumonia. Nonetheless, we need more randomized clinical trials (RCTs) and treatment guidelines for developing effective management of the 2019-nCoV and improve patient outcomes by reducing mortality in high-risk patients. We also need more clinical trials and management guidelines for the effective management of 2019-nCoV pneumonia.

27 May 2024 in Acta Cardiologica
Verified
Journal Article
Closed access
NPNeev Patel
Neev Patel
BCBruno Alvarez Concejo
Bruno Alvarez Concejo
KLKevin Bryan Lo
Kevin Bryan Lo
MMMeenakshi Mishra
Meenakshi Mishra
AKAyeesha Kattubadi
Ayeesha Kattubadi
JRJanani Rangaswami
Janani Rangaswami
Background: Midodrine, an FDA-approved medication for orthostatic hypotension, is also used off-label to manage hypotension in dialysis patients, including those with heart failure. However, in patients with reduced ejection fraction (HFrEF) and/or right heart failure, midodrine is potentially harmful. No known studies examine the safety of midodrine in hospitalised kidney failure patients with HF. Methods: The TriNetX database was queried for hospitalised kidney failure patients with HFrEF and/or right heart failure who experienced hypotension (SBP < 110 mm Hg or MAP < 70 mm Hg). Excluding those needing critical care or vasopressors, we compared cohorts based on midodrine use, matching for comorbidities. Results: Analysis showed patients on midodrine had a higher 6-month mortality risk ratio (RR 1.53, 95% CI 1.037 to 2.246) and Hazard Ratio (HR 1.54, 95% CI 1.022 to 2.317) compared to those not on midodrine, indicating an association with increased mortality. Conclusion: This study illuminates the complexities in treating hospitalised patients with kidney failure and HF. Our findings, drawn from an exploratory analysis, indicate that inpatient midodrine use is associated with increased 6-month mortality. This may reflect deleterious effects from vasoconstriction and/or unmeasured confounders in this vulnerable population. This investigation, utilising TriNetX, was limited by access to deidentified aggregate data, preventing detailed exploration of specifics such as timing, dosage, and indications for midodrine use. Moreover, given its observational nature, cause-effect relationship cannot be established. Our findings indicate an increased mortality associated with midodrine use for hypotension, underscoring the need for further research and consideration of alternative strategies.

14 May 2026 in Clinical Case Reports
Verified
Journal Article
Open access
PDF file
RBRebecca Boyle
Rebecca Boyle
NPNeev Patel
Neev Patel
A 65‐year‐old man, one year post combined heart‐kidney transplant, presented with acute kidney injury, dyspnea, and progressive leg edema unresponsive to escalating diuretics. Despite suspicion for volume overload, multi‐organ point‐of‐care ultrasound (POCUS) revealed bilateral A‐lines without B‐lines or effusions, a small collapsible inferior vena cava, and preserved biventricular function, all inconsistent with cardiogenic congestion. The edema was attributed to sirolimus‐associated lymphedema. Diuretic cessation and transition from sirolimus to everolimus improved renal function. This case illustrates the utility of integrated multi‐organ POCUS in challenging assumptions about volume status and underscores the importance of contextualizing findings across multiple sonographic windows.

25 July 2020 in Cureus
Verified
Journal Article
Open access
PDF file
PKPawandeep Kaur
Pawandeep Kaur
TATemitope Ajibawo
Temitope Ajibawo
TYTimiiye Yomi
Timiiye Yomi
NPNeev Patel
Neev Patel
MBMizba Baksh
Mizba Baksh
Rikinkumar S. PatelRikinkumar S. Patel
Rikinkumar S. Patel
Our study aimed to assess the risk of in-patient mortality due to renal failure and other comorbidities in aortic stenosis (AS) patients undergoing transcatheter aortic valve replacement (TAVR). We conducted a cross-sectional study using a Nationwide Inpatient Sample (NIS, January 2010 to December 2014) from the United States and included 33,325 patients with a primary diagnosis of AS. Logistic regression was used to evaluate the odds ratio (OR) for in-hospital mortality in AS by comorbidities including renal failure. The prevalence of renal failure in AS patients is 29.2%, and a higher proportion were males (60.1%) and non-white (14.1%). Major loss of function (96.6%) and in-hospital mortality (5.1%) were also proportionally higher in prevalence. Female patients (OR 1.35, 95% CI 1.20-1.51) had higher odds of in-patient mortality in AS patients. Race was a non-significant predictor for mortality risk. Patients with comorbid coagulopathy (OR 2.02, 95% CI 1.79-2.27) and heart failure (OR 1.62, 95% CI 1.39-1.89) have increased mortality in AS inpatients. After controlling confounders, renal failure was significantly associated with increased in-hospital mortality (OR 1.43, 95% CI 1.28-1.61) in AS patients. Renal failure was prevalent in AS patients and was an independent factor that increases the risk of in-hospital mortality by 43%. Due to worse outcomes, more studies are required to evaluate risk-benefit ratio and strategies to improve health-related quality of life in post-TAVR patients with renal failure, and optimally decrease inpatient mortality.